News
What changed for people on GLP-1 treatment
Medicines (approvals, safety, access), nutrition and exercise. Only what changes something for you, with the date and the source on every item. No miracle cures, no promises.
Last checked: 16 November 2026
Sources: EMA · FDA · MHRA · medical journals · manufacturers
How we check an item →November 2026
9 NovMedicinesSafety
Your eyes: a rare sign worth knowing
For you: if the vision in one eye drops suddenly and without pain, see a doctor the same day. It is rare, and knowing the sign gets you checked quickly.
Source: FDA — Drug Safety Communication, 9 November 2026 · EMA — PRAC: NAION a very rare side effect of semaglutide, 6 June 2025MounjaroOzempicWegovy
October 2026
15 OctMedicinesApprovals
The daily GLP-1 pill Foundayo: already in the US and the UK, now recommended for the EU
For you: in the US and the UK it is available on prescription. In the EU it is not in pharmacies yet.
Source: EMA — New oral GLP-1 medicine for weight management and type 2 diabetes, 16 October 2026 · MHRA — UK first in Europe to authorise orforglipron, 10 August 2026 · AJMC — FDA approves Lilly's oral GLP-1 orforglipron for obesity, 1 April 2026
September 2026
29 SepMedicinesStudy
Research moves forward: the main retatrutide trial is published
For you: it is still an investigational medicine. The treatment you have now is the one to follow.
Source: New England Journal of Medicine, 29 September 2026 (Jastreboff et al., TRIUMPH-1) — reported by Scientific American · Eli Lilly — TRIUMPH-2 and TRIUMPH-3 results, 23 July 2026 · Reuters via FOX 9 — Eli Lilly offers retatrutide to some patients before FDA approval, 7 August 2026